ESMO Immuno-Oncology 2022 | FOXC1 as a novel prognostic biomarker in immune checkpoint inhibitor therapy

Partha Ray, MD, Onconostic Technologies, Evanston, IL, discusses novel biomarkers to assess the efficacy of immune checkpoint inhibitors. Whilst current biomarkers such as MKI67, which can monitor tumor proliferation, and PD-L1 are currently utilized to predict response to immunotherapy, there is an unmet need in terms of optimizing efficacy. The addition of FOXC1 as a third biomarker can measure plasticity in cancer cells, and has been assessed in data sets from the I-SPY trial (NCT01042379) in patients with breast cancer. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.